期刊文献+

Krüppel样因子5在小鼠舌黏膜癌变过程中的表达 被引量:2

Expression of KLF5 in 4NQO-induced mouse tongue carcinogenesis
下载PDF
导出
摘要 目的检测Krüppel样因子5(Krüppel-like factor 5,KLF5)在小鼠舌黏膜癌变模型中的表达,探讨KLF5与口腔黏膜癌变的关系。方法将42只C57BL/6J小鼠随机分为阴性对照组、4-硝基喹啉-1-氧化物(4NQO)处理组。阴性对照组不做任何处理,4NQO组以4NQO水溶液(50μg/ml)代替饮用水饲养,共16周。实验第24周末处死全部动物,取舌组织进行HE染色及KLF5平均光密度值分析。结果 HE染色显示,对照组小鼠舌背上皮为正常角化的复层鳞状上皮,饮用4NQO水溶液的小鼠舌黏膜上皮出现了不同程度的异常增生及鳞癌。平均光密度测定显示,与正常口腔黏膜上皮相比,KLF5在重度异常增生和鳞癌中的表达明显下降(P<0.01)。结论 KLF5可能在口腔黏膜上皮癌变过程中作为肿瘤抑制基因发挥重要作用。 Objective To examine the expression of KLF5 in 4NQO-induced mouse tongue carcinogenesis. Methods Forty-two C57BL/6J mice were divided into two groups, control group (without any treatment) and 4NQO group, in which the mice were given 4NQO(50μg/ml) in drinking water for 16 weeks. At the end of 24thweek , the mice were sacrificed and their tongues were harvested for HE staining and immunohistoehemistry. Results HE staining showed that normal stratified squamous epithelium were observed in the tongues of the control, and mild to severe dysplasia and even to squamous cell carcinoma lesions appeared in the tongues of 4NQO group. Immunohistochemistry results showed that the KLF5 displayed a strong nuclear staining in normal tongue mucosa. The expression of KLF5 markedly decreased in the severe dysplasia to squamous cell carcinomas, which was significantly different with that in the control group ( P 〈 0.01 ). Conclusion KLFS may serve as a tumor suppressor gene in oral carcinogenesis.
出处 《北京口腔医学》 CAS 2014年第3期125-128,共4页 Beijing Journal of Stomatology
基金 国家自然科学基金(81272982) 北京市卫生系统高层次卫生人才基金(2011-3-073)
关键词 KLF5 口腔鳞癌 动物模型 KLF5 Oral carcinogenesis Animal models
  • 相关文献

参考文献11

  • 1宿颖,葛丽华,苗聪聪,张敏,张辛燕.三氧化二砷对口腔鳞癌细胞裸鼠移植瘤的抑制作用[J].北京口腔医学,2013,21(1):1-5. 被引量:6
  • 2龚邵新,庄英帜,赵强,贺荣芳,丁慧,胡义燕,阳帅,曾庆彪.KLF4和KLF5蛋白在不同临床分期胃癌组织中的表达及意义[J].中国癌症杂志,2010,20(10):756-759. 被引量:11
  • 3Chen C, Bhalala HV, Qiao H, et al. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene, 2002, 21 (43): 6567-6572.
  • 4Yang Y, Tarapore RS, Jarmel MH, et al. p53 mutation aliens the effect of the esophageal tumor suppressor KLF5 on keratinocyte proliferation. Cell Cycle, 2012, 11 (21 ) : 4033-4039.
  • 5Sun R, Chen X, Yang VW. Intestinal-enriched Kriippel-like factor (Krtippel-like factor 5 ) is a positive regulator of cellular proliferation. J Biol Chem, 2001, 276(10) : 6897-6900.
  • 6Chen C, Benjamin MS, Sun X, et al. KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU - Prl human bladder cancer cell line. Int J Cancer, 2006, 118 (6) : 1346-1355.
  • 7Nandan MO, Yoon HS, Zhao W, et al. Krtlppel-like faetor 5 mediates the transforming activity of oneogenie H-Ras. Oncogene, 2004, 23(19) : 3404-3413.
  • 8Nandan MO, Chanchevalap S, Dalton WB, et al. Krtippel-like factor 5 promotes mitosis by activating the cyclin B1/Cde2 complex during oncogenic Ras-mediated transformation. FEBS Left, 2005, 579 (21) : 4757-4762.
  • 9Bateman NW, Tan D, Pestell RG, et al. Intestinal tumor progression is associated with altered function of KLF5. J Biol Chem, 2004, 279 (13) : 12093-12101.
  • 10Yang Y, Goldstein BG, Chao HH, et al. KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther, 2005, 4( 11 ) : 1216-1221.

二级参考文献15

  • 1倪建华,陈国强,沈志祥,李秀松,刘海卫,黄燕婷,方智雯,陈赛娟,王振义,陈竺.静脉滴注三氧化二砷治疗急性早幼粒细胞白血病的药代动力学分析[J].中华血液学杂志,1997,18(5):250-253. 被引量:100
  • 2Wamakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncology, 2009,45 (4-5) :309-316.
  • 3Uarsh D, Suchak K, Moutasim KA. Stromal features are predictive of disease mortality in oral cancer patients. J Pathol, 2011 (4), 223 : 470-481.
  • 4Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist, 2001,6 ( Suppl 2 ) : 1-2.
  • 5Bomstein J, Sagi S, Haj A, et al. Arsenic trioxide inhibits the growth of human ovarian carcinoma cell line. Gynecol Onco, 2005,99 ( 3 ) : 726-729.
  • 6Cheng B, Yang X, Han Z, et al. Arsenic trioxide induced theapoptosis of laryngeal cancer via down-regulation of survivin mRNA. Auris Nasus Larynx,2008,35 ( 1 ) : 95-101.
  • 7Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev, 2007, 33 (6) : 542-564.
  • 8Efferth T, Li PC, Konkimalla VS, et al. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med ,2007,13 (8) : 353-361.
  • 9Gazitt Y. Akay C. Arsenic trioxide: an anti cancer missile with multiple warheads. Hematology,2005, 10(3) : 205-213.
  • 10Kumar P, Benedict R, Urzua F, et al. Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest ,2005, 85 (6) : 756- 767.

共引文献15

同被引文献7

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部